Research analysts at Morgan Stanley assumed coverage on shares of Vitamin Shoppe (NYSE:VSI) in a note issued to investors on Monday, The Fly reports. The brokerage set an “equal weight” rating and a $14.00 price target on the specialty retailer’s stock. Morgan Stanley’s price objective points to a potential upside of 16.67% from the stock’s current price.

A number of other research firms have also weighed in on VSI. ValuEngine raised shares of Vitamin Shoppe from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 4th. Barclays lowered shares of Vitamin Shoppe from an “equal weight” rating to an “underweight” rating in a report on Friday, September 7th. Finally, Zacks Investment Research raised shares of Vitamin Shoppe from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st.

VSI stock opened at $12.00 on Monday. Vitamin Shoppe has a fifty-two week low of $2.95 and a fifty-two week high of $13.95. The company has a quick ratio of 0.32, a current ratio of 1.96 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $301.86 million, a P/E ratio of 30.51 and a beta of 0.72.

Vitamin Shoppe (NYSE:VSI) last posted its earnings results on Wednesday, August 8th. The specialty retailer reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.27. Vitamin Shoppe had a negative net margin of 8.76% and a positive return on equity of 2.42%. The firm had revenue of $293.10 million during the quarter, compared to analyst estimates of $279.87 million. analysts predict that Vitamin Shoppe will post 0.13 earnings per share for the current year.

In other news, Director Guillermo Marmol acquired 8,900 shares of the company’s stock in a transaction on Friday, August 10th. The stock was bought at an average cost of $11.21 per share, with a total value of $99,769.00. Following the completion of the purchase, the director now directly owns 49,479 shares of the company’s stock, valued at $554,659.59. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sharon M. Leite acquired 5,500 shares of the company’s stock in a transaction on Friday, August 31st. The shares were purchased at an average cost of $12.64 per share, with a total value of $69,520.00. Following the completion of the purchase, the chief executive officer now directly owns 5,500 shares of the company’s stock, valued at $69,520. The disclosure for this purchase can be found here. Company insiders own 18.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of VSI. Trexquant Investment LP purchased a new position in Vitamin Shoppe during the second quarter worth $105,000. GSA Capital Partners LLP purchased a new position in Vitamin Shoppe during the first quarter worth $109,000. Nisa Investment Advisors LLC purchased a new position in Vitamin Shoppe during the second quarter worth $129,000. Spark Investment Management LLC purchased a new position in Vitamin Shoppe during the second quarter worth $227,000. Finally, AJ Wealth Strategies LLC purchased a new position in Vitamin Shoppe during the second quarter worth $266,000. 89.55% of the stock is owned by institutional investors.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

See Also: S&P 500 Index

The Fly

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.